Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
7 "Hee Jin Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Standardized pathology report for breast cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
J Pathol Transl Med. 2021;55(1):1-15.   Published online January 11, 2021
DOI: https://doi.org/10.4132/jptm.2020.11.20
  • 7,953 View
  • 590 Download
  • 6 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary Material
Given the recent advances in management and understanding of breast cancer, a standardized pathology report reflecting these changes is critical. To meet this need, the Breast Pathology Study Group of the Korean Society of Pathologists has developed a standardized pathology reporting format for breast cancer, consisting of ‘standard data elements,’ ‘conditional data elements,’ and a biomarker report form. The ‘standard data elements’ consist of the basic pathologic features used for prognostication, while other factors related to prognosis or diagnosis are described in the ‘conditional data elements.’ In addition to standard data elements, all recommended issues are also presented. We expect that this standardized pathology report for breast cancer will improve diagnostic concordance and communication between pathologists and clinicians, as well as between pathologists inter-institutionally.

Citations

Citations to this article as recorded by  
  • Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response
    Hyunwoo Lee, Yunjeong Jang, Yoon Ah Cho, Eun Yoon Cho
    Human Pathology.2024; 145: 1.     CrossRef
  • Sentinel lymph node biopsy in patients with ductal carcinomain situ: systematic review and meta-analysis
    Matthew G. Davey, Colm O’Flaherty, Eoin F. Cleere, Aoife Nohilly, James Phelan, Evan Ronane, Aoife J. Lowery, Michael J. Kerin
    BJS Open.2022;[Epub]     CrossRef
Original Articles
Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
J Pathol Transl Med. 2019;53(3):180-187.   Published online March 11, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.08
  • 6,575 View
  • 196 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Background
Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC.
Methods
In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression.
Results
No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups.
Conclusions
High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.

Citations

Citations to this article as recorded by  
  • Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
    Sotiris Loizides, Anastasia Constantinidou
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Prognostic benefit of TILs independent of clinicopathological and molecular factors
    Koen Brummel, Anneke L. Eerkens, Marco de Bruyn, Hans W. Nijman
    British Journal of Cancer.2023; 129(5): 737.     CrossRef
  • Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
    Rupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Michael Gnant, Marija Balic, Thamer Sliwa, Christian Singer
    Wiener klinische Wochenschrift.2023;[Epub]     CrossRef
  • Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
    Xinyu Zhou, Abel Soto-Gamez, Fleur Nijdam, Rita Setroikromo, Wim J. Quax
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
    Andrii Puzyrenko, Chandler S Cortina, Julie M Jorns
    International Journal of Surgical Pathology.2022; 30(7): 728.     CrossRef
  • Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
    Shengnan Sha, Luyi Si, Xinrui Wu, Yuanbiao Chen, Hui Xiong, Ying Xu, Wangrui Liu, Haijun Mei, Tao Wang, Mei Li
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
    Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
    Cancer Investigation.2022; 40(10): 879.     CrossRef
  • Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
    Arpita Poddar, Sushma R. Rao, Prashanth Prithviraj, George Kannourakis, Aparna Jayachandran
    Current Oncology.2022; 29(10): 6847.     CrossRef
  • The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
    Natsuki Furukawa, Vered Stearns, Cesar A. Santa-Maria, Aleksander S. Popel
    Expert Opinion on Therapeutic Targets.2022; 26(12): 1041.     CrossRef
  • Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions
    Katarzyna Dominika Sluzalska, Jakub Slawski, Martyna Sochacka, Agata Lampart, Jacek Otlewski, Malgorzata Zakrzewska
    Cytokine & Growth Factor Reviews.2021; 57: 93.     CrossRef
  • Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
    Hiu Yee Kwan, Qinghua Xu, Ruihong Gong, Zhaoxiang Bian, Chih-Chang Chu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
    Marie Colombe Agahozo, Marcel Smid, Ronald van Marion, Dora Hammerl, Thierry P. P. van den Bosch, Mieke A. M. Timmermans, Chayenne J. Heijerman, Pieter J. Westenend, Reno Debets, John W. M. Martens, Carolien H. M. van Deurzen
    Biology.2021; 10(8): 768.     CrossRef
  • With Our Powers Combined
    Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
    The Cancer Journal.2021; 27(6): 511.     CrossRef
  • The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer


    Li Chen, Xiangyi Kong, Chengrui Yan, Yi Fang, Jing Wang
    OncoTargets and Therapy.2020; Volume 13: 1397.     CrossRef
  • Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer


    Xenia Elena Bacinschi, Anca Zgura, Inga Safta, Rodica Anghel
    Cancer Management and Research.2020; Volume 12: 11965.     CrossRef
WITHDRAWN:A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey
Myunghee Kang, Seung Yeon Ha, Joung Ho Han, Mee Sook Roh, Se Jin Jang, Hee Jin Lee, Heae Surng Park, Geon Kook Lee, Kyo Young Lee, Jin-Haeng Chung, Yoo Duk Choi, Chang Hun Lee, Lucia Kim, Myoung Ja Chung, Soon Hee Jung, Gou Young Kim, Wan-Seop Kim
Received April 4, 2018  Accepted July 9, 2018  Published online July 16, 2018  
DOI: https://doi.org/10.4132/jptm.2018.07.10    [Accepted]
  • 4,865 View
  • 63 Download
Case Report
Rosai-Dorfman Disease: Report of a Case Associated with IgG4-Related Sclerotic Lesions
Bong-Hee Park, Da Hye Son, Myung-Hwan Kim, Tae Sun Shim, Hee Jin Lee, Jooryung Huh
Korean J Pathol. 2012;46(6):583-586.   Published online December 26, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.583
  • 6,869 View
  • 51 Download
  • 5 Crossref
AbstractAbstract PDF

We describe a rare case of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) associated with a six-year history of autoimmune pancreatitis, which was controlled by steroid treatment. The patient presented with multiple, cervical and thoracic lymphadenopathy and abnormal, nodular opacities in the lung. Histologically, Rosai-Dorfman disease with numerous IgG4-positive cells was identified in a subcutaneous lymph node in the patient's left forearm. The patient recovered uneventfully with steroid treatment.

Citations

Citations to this article as recorded by  
  • Lung Involvement in Destombes-Rosai-Dorfman Disease
    Quentin Moyon, Samia Boussouar, Philippe Maksud, Jean-François Emile, Frédéric Charlotte, Nathalie Aladjidi, Grégoire Prévot, Jean Donadieu, Zahir Amoura, Philippe Grenier, Julien Haroche, Fleur Cohen Aubart
    Chest.2020; 157(2): 323.     CrossRef
  • Rosai-Dorfman Disease: Rare Pulmonary Involvement Mimicking Pulmonary Langerhans Cell Histiocytosis and Review of the Literature
    Rashid AL Umairi, Danielle Blunt, Wedad Hana, Matthew Cheung, Anastasia Oikonomou
    Case Reports in Radiology.2018; 2018: 1.     CrossRef
  • IgG4‐related skin disease may have distinct systemic manifestations: a systematic review
    Adam E. Bennett, Neil A. Fenske, Paul Rodriguez‐Waitkus, Jane L. Messina
    International Journal of Dermatology.2016; 55(11): 1184.     CrossRef
  • Nosology and Pathology of Langerhans Cell Histiocytosis
    Jennifer Picarsic, Ronald Jaffe
    Hematology/Oncology Clinics of North America.2015; 29(5): 799.     CrossRef
  • A subset of Rosai–Dorfman disease cases show increased IgG4‐positive plasma cells: another red herring or a true association with IgG4‐related disease?
    Madhu P Menon, Moses O Evbuomwan, Juan Rosai, Elaine S Jaffe, Stefania Pittaluga
    Histopathology.2014; 64(3): 455.     CrossRef
Original Articles
The Ratio of Atypical Ductal Hyperplasia Foci to Core Numbers in Needle Biopsy: A Practical Index Predicting Breast Cancer in Subsequent Excision
Jeong-Ju Lee, Hee Jin Lee, Jun Kang, Jeong-Hyeon Jo, Gyungyub Gong
Korean J Pathol. 2012;46(1):15-21.   Published online February 23, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.1.15
  • 9,709 View
  • 40 Download
  • 1 Crossref
AbstractAbstract PDF
Background

Although core needle biopsy (CNB) is considered to be the standard technique for histological diagnosis of breast lesions, it is less reliable for diagnosing atypical ductal hyperplasia (ADH). We therefore assessed the characteristics of CNB-diagnosed ADH that are more likely to be associated with more advanced lesions on subsequent surgical excision.

Methods

We retrospectively examined 239 consecutive CNBs, 127 of which were diagnosed as ADH following surgical excision, performed at Asan Medical Center between 1995 and 2010. Archival slides were analyzed for the number of cores per specimen, the number of ADH foci, and the ratio of ADH foci to number of cores (FC ratio).

Results

We found that ADH foci in 3 or more cores (p=0.003) and the presence of ADH in 3 or more foci (p=0.002) were correlated with malignancy following excision lesion. Moreover, an FC>1.1 was significantly associated with malignancy in the subsequent excision (p=0.000).

Conclusions

Including the number of ADH foci, the number of cores involved according to ADH, FC ratio, and histologic type in a pathology report of CNB may help in making clinical decisions about surgical excision.

Citations

Citations to this article as recorded by  
  • Active Surveillance for Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ
    Rachel Miceli, Cecilia L Mercado, Osvaldo Hernandez, Chloe Chhor
    Journal of Breast Imaging.2023; 5(4): 396.     CrossRef
Histologic Parameters Predicting Survival of Patients with Multiple Non-small Cell Lung Cancers.
Joo Young Kim, Hee Jin Lee, Jun Kang, Se Jin Jang
Korean J Pathol. 2011;45(5):506-515.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.5.506
  • 2,774 View
  • 17 Download
AbstractAbstract PDF
BACKGROUND
In multiple lung cancers (MLCs), distinction between intrapulmonary metastases and multiple primary tumors is important for staging and prognosis. In this study, we have investigated histopathologic prognostic factors of patients with MLCs.
METHODS
Histologic subtype, size differences, lobar location, lymphovascular invasion (LVI), size of the largest tumor, nodal status, number of tumors, morphology of tumor periphery, and immunohistochemical profiles using eight antibodies, were analyzed in 65 patients with MLCs.
RESULTS
There was no significant difference in the survivals of patients with multiple primary tumors and intrapulmonary metastases, as determined by the Martini-Melamed criteria (p=0.654). Risk grouping by four histologic parameters, LVI, margin morphology, size differences, and lobar locations of paired tumors were prognostic. The patients with one or two of aforementioned parameters had significantly longer survival than those with three or four parameters (p=0.017). In patients with largest mass (< or =5 cm), the risk grouping was found to be an independent prognostic factor (p=0.022). However, differences in immunohistochemical staining were not related to patients' survival.
CONCLUSIONS
A risk grouping of MLC patients by using combinations of histologic parameters can be a useful tool in evaluating the survival of patients with MLCs, and may indicate clonal relationship between multiple tumors.
Case Report
Juxtacortical Glomus Tumor of the Tibia with an Uncertain Malignant Potential.
Dae Woon Eom, Gil Hyun Kang, Hee Jin Lee, Soo Jung Choi, Jae kwang Hwang
Korean J Pathol. 2008;42(3):181-184.
  • 1,881 View
  • 32 Download
AbstractAbstract PDF
Glomus tumors are mesenchymal neoplasms that are composed of modified smooth muscle cells of the normal glomus body. Most glomus tumors are benign and they occur in the distal extremities, and particularly the subungual lesions that occur in the hand, the wrist and the foot. We report here on a case of a solid type glomus tumor that had an uncertain malignant potential with a juxtacortical location at the distal tibia, and there were no neoplastic erosion of the cortical surface and no periosteal reaction. The tumor cells showed mild nuclear atypia and moderate mitotic activity (3-5/10HPF). Prominent intranuclear cytoplasmic pseudoinclusions were also observed. This case is interesting due to the very unusual tumor location of the juxtacortical area of the long bone, the atypical histologic features and the unique cytological finding of cytoplasmic intranuclear inclusions throughout the tumor cells.

J Pathol Transl Med : Journal of Pathology and Translational Medicine